Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by James S. Ferriss
Ascites Predicts Treatment Benefit of Bevacizumab in Front-Line Therapy of Advanced Epithelial Ovarian, Fallopian Tube and Peritoneal Cancers: An NRG Oncology/Gog Study
Gynecologic Oncology
Gynecology
Oncology
Obstetrics
Related publications
Phase II Study of Bevacizumab and Pemetrexed for Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Gynecologic Oncology
Gynecology
Oncology
Obstetrics
A Phase II Study of the Combination Chemotherapy of Bevacizumab and Gemcitabine in Women With Platinum-Resistant Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Journal of Ovarian Research
Gynecology
Oncology
Obstetrics
An Open-Label, Randomized, Phase II Trial Evaluating the Efficacy and Safety of Standard of Care With or Without Bevacizumab in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Previously Treated With Bevacizumab for Front-Line or Platinum-Sensitive Ovarian Cancer: Rationale, Design, and Methods of the Japanese Gynecologic Oncology Group Study JGOG3023
BMC Cancer
Cancer Research
Oncology
Genetics
Salpingo-Oophorectomy and the Risk of Ovarian, Fallopian Tube, and Peritoneal Cancers in Women With a BRCA1 or BRCA2 Mutation
JAMA - Journal of the American Medical Association
Medicine
The Prognostic Value of Morphometry in Advanced Epithelial Ovarian Cancers
British Journal of Cancer
Cancer Research
Oncology
Phase 1–2 Study of Docetaxel Plus Aflibercept in Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
The Lancet Oncology
Oncology
Erratum To: The New WHO Classification of Ovarian, Fallopian Tube, and Primary Peritoneal Cancer and Its Clinical Implications
Archives of Gynecology and Obstetrics
Medicine
Gynecology
Obstetrics
Ovarian Cancer May Originate in the Fallopian Tube
Cancer Discovery
Oncology
Follow-Up of Patients Who Are Clinically Disease-Free After Primary Treatment for Fallopian Tube, Primary Peritoneal, or Epithelial Ovarian Cancer: A Program in Evidence-Based Care Guideline Adaptation
Current Oncology
Oncology
